SCHEMBL6318004

SCHEMBL6318004

COc1cc(N)ccc1CCC(=O)N1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
GAA P10253 2/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
KDM4E B2RXH2 2/20 0.47
RAB9A P51151 1/20 0.47
RAD52 P43351 1/20 0.45
GFER P55789 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.44
OXTR P30559 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5381731 0.81 KMT2A (0.54) MAPTMAPK1HTTMEN1KMT2A
SCHEMBL22813637 0.81 KMT2A (0.69) MEN1KMT2ATDP1KDM4ENPC1
SCHEMBL8328272 0.80 KMT2A (0.67) MAPTMEN1KMT2AALDH1A1TDP1
SCHEMBL14931999 0.79 GAA (0.59) MAPTGAATSHRMAPK1HTT
SCHEMBL1531406 0.77 GAA (0.57) MAPTGAATSHRMAPK1HTT
SCHEMBL1930008 0.77 ALDH1A1 (0.69) GAATSHRHTTMEN1KMT2A
SCHEMBL6319823 0.76 KMT2A (0.48) MAPTMEN1KMT2AALDH1A1TDP1
SCHEMBL13946459 0.76 SMN1; SMN2 (0.64) GAATSHRHTTMEN1KMT2A
SCHEMBL12426803 0.74 GAA (0.53) MAPTGAATSHRMAPK1HTT
SCHEMBL2076533 0.74 MAPT (0.53) MAPTGAATSHRMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939874-B2 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. (US) 2005-09-06 US disclosed
EP-1427421-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS Amgen Inc. (US) 2004-06-16 EP disclosed
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. 2004-04-01 US disclosed
WO-2003018021-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS AMGEN INC. (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use DPYD, TYMP, TPMT MAPT 4491/4885GAA 1184/4885TSHR 3359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.